Related references
Note: Only part of the references are listed.NIMG-18. EFFECT OF BEVACIZUMAB AGAINST CYSTIC PART OF BRAIN TUMOR
Fumiyuki Yamasaki et al.
NEURO-ONCOLOGY (2019)
Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma
Nataliya Zhukova et al.
CANCER MEDICINE (2019)
Angiogenesis in melanoma: an update with a focus on current targeted therapies
George Jour et al.
JOURNAL OF CLINICAL PATHOLOGY (2016)
Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma
Ayseguel Ilhan-Mutlu et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
Pippa G. Corrie et al.
LANCET ONCOLOGY (2014)
Bevacizumab and central nervous system (CNS) hemorrhage
Nathalie Letarte et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Primary Spinal Cord Melanoma
Min Soo Kim et al.
JOURNAL OF KOREAN NEUROSURGICAL SOCIETY (2010)
Share Paper
